Fewer new drugs for rare disorders come to Canada relative to the US and Europe. Canada has set-up barriers that delay or deny access to new drugs for many patients with unmet or poorly met healthcare needs. This leaves vulnerable Canadians at a serious disadvantage.
This webinar highlights how these barriers impact Canadians living with rare disorders, how the federal government made matters worse over the past six years with well-intentioned but poorly conceived plans to reduce drug prices, and why the result has been greater uncertainty and further delays. Panelists also discuss the impact of a proposed national pharmacare program and alternative ways to help ensure Canadians, especially those with rare disorders, have access to the drugs they need.